Catalyst overview
Research summary
This catalyst tracks a Phase 1 data readout for REC-4539 in Small cell lung cancer, Cancer. The expected timing is based on the latest available company guidance and may change.
1/7/25- FDA cleared IND application. 5/5/25- Advancing additional discovery programs to meet key criteria. 11/05/25:- PR No update. 02/25/26:- Early Ph1 monotherapy safety and PK data expected in H2 2027. 05/06/26:- ENLYGHT Ph1 solid tumor study dosed first patient in April. Early safety and PK data expected H2 2027. 08/05/26:- Early Ph1 monotherapy safety and PK data reiterated for H2 2027.
Verification
Confirm timing and program details against the company announcement or filing.